Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellular Senescence | 6 | 2026 | 226 | 0.970 |
Why?
|
| Flavonols | 3 | 2026 | 27 | 0.650 |
Why?
|
| Vascular Stiffness | 5 | 2025 | 487 | 0.620 |
Why?
|
| Doxorubicin | 3 | 2026 | 403 | 0.580 |
Why?
|
| Vascular Diseases | 3 | 2023 | 252 | 0.470 |
Why?
|
| Flavonoids | 2 | 2026 | 85 | 0.440 |
Why?
|
| Exercise Tolerance | 3 | 2026 | 283 | 0.430 |
Why?
|
| Sympathetic Nervous System | 2 | 2026 | 181 | 0.420 |
Why?
|
| Aorta | 3 | 2025 | 440 | 0.400 |
Why?
|
| Oxidative Stress | 5 | 2026 | 1359 | 0.380 |
Why?
|
| Endothelial Cells | 8 | 2026 | 877 | 0.270 |
Why?
|
| Dietary Supplements | 3 | 2026 | 584 | 0.240 |
Why?
|
| Pulse Wave Analysis | 5 | 2025 | 267 | 0.240 |
Why?
|
| Trastuzumab | 1 | 2026 | 118 | 0.220 |
Why?
|
| Pyruvaldehyde | 1 | 2025 | 46 | 0.220 |
Why?
|
| Interferon Regulatory Factors | 1 | 2025 | 45 | 0.220 |
Why?
|
| Arteries | 2 | 2023 | 261 | 0.220 |
Why?
|
| Glycation End Products, Advanced | 1 | 2025 | 81 | 0.220 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.210 |
Why?
|
| Mitochondria | 3 | 2026 | 992 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2025 | 140 | 0.210 |
Why?
|
| Toll-Like Receptors | 1 | 2025 | 193 | 0.210 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2024 | 31 | 0.200 |
Why?
|
| Smoking Water Pipes | 1 | 2023 | 9 | 0.200 |
Why?
|
| Spermidine | 1 | 2024 | 18 | 0.200 |
Why?
|
| Water Pipe Smoking | 1 | 2023 | 9 | 0.200 |
Why?
|
| Endothelium, Vascular | 3 | 2025 | 956 | 0.200 |
Why?
|
| Nucleic Acids | 1 | 2024 | 70 | 0.190 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 103 | 0.190 |
Why?
|
| NAD | 1 | 2023 | 79 | 0.190 |
Why?
|
| Elastin | 1 | 2023 | 78 | 0.190 |
Why?
|
| Postmenopause | 1 | 2025 | 394 | 0.180 |
Why?
|
| Vaping | 1 | 2023 | 74 | 0.180 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2023 | 110 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 143 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 7 | 2026 | 5992 | 0.170 |
Why?
|
| Aging | 4 | 2025 | 1973 | 0.170 |
Why?
|
| Vasodilation | 1 | 2025 | 521 | 0.170 |
Why?
|
| Reactive Oxygen Species | 4 | 2025 | 611 | 0.160 |
Why?
|
| Resistance Training | 1 | 2023 | 186 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2026 | 338 | 0.160 |
Why?
|
| Muscle, Skeletal | 3 | 2025 | 1791 | 0.160 |
Why?
|
| Antioxidants | 1 | 2023 | 550 | 0.150 |
Why?
|
| Motor Activity | 1 | 2024 | 718 | 0.140 |
Why?
|
| Inflammation | 3 | 2025 | 2883 | 0.140 |
Why?
|
| Dementia | 1 | 2023 | 328 | 0.140 |
Why?
|
| Mice | 9 | 2026 | 18355 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1969 | 0.120 |
Why?
|
| Nitric Oxide | 3 | 2023 | 892 | 0.100 |
Why?
|
| Animals | 9 | 2026 | 38097 | 0.100 |
Why?
|
| Aniline Compounds | 2 | 2025 | 120 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 2393 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2191 | 0.090 |
Why?
|
| Brachial Artery | 2 | 2025 | 208 | 0.090 |
Why?
|
| Humans | 16 | 2026 | 145763 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 610 | 0.080 |
Why?
|
| Sulfonamides | 2 | 2025 | 583 | 0.080 |
Why?
|
| Male | 9 | 2026 | 73003 | 0.070 |
Why?
|
| THP-1 Cells | 1 | 2025 | 19 | 0.060 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2025 | 8 | 0.060 |
Why?
|
| Middle Aged | 5 | 2026 | 36302 | 0.060 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2025 | 43 | 0.060 |
Why?
|
| Imidazoles | 1 | 2025 | 247 | 0.050 |
Why?
|
| Premenopause | 1 | 2025 | 125 | 0.050 |
Why?
|
| Hand Strength | 1 | 2025 | 144 | 0.050 |
Why?
|
| Female | 7 | 2026 | 79035 | 0.050 |
Why?
|
| Standard of Care | 1 | 2024 | 81 | 0.050 |
Why?
|
| Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.050 |
Why?
|
| Respiratory Muscles | 1 | 2023 | 37 | 0.050 |
Why?
|
| Aged | 4 | 2025 | 26215 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2023 | 119 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2023 | 209 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 238 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 131 | 0.050 |
Why?
|
| Monocytes | 1 | 2025 | 539 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 227 | 0.040 |
Why?
|
| DNA Damage | 1 | 2024 | 437 | 0.040 |
Why?
|
| Adult | 4 | 2026 | 40872 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 936 | 0.040 |
Why?
|
| Nicotine | 1 | 2023 | 331 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2025 | 1708 | 0.040 |
Why?
|
| RNA Polymerase II | 1 | 2024 | 350 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2023 | 332 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2026 | 3634 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 981 | 0.030 |
Why?
|
| Cytokines | 1 | 2025 | 2069 | 0.030 |
Why?
|
| Oxygen | 1 | 2022 | 981 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2025 | 4151 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2514 | 0.030 |
Why?
|
| Young Adult | 2 | 2023 | 14251 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3551 | 0.030 |
Why?
|
| Apoptosis | 1 | 2024 | 2443 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 4568 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 5223 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 8346 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 22573 | 0.010 |
Why?
|